BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have earned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $140.0314.

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research note on Thursday, December 11th. Bank of America lowered their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Morgan Stanley reiterated an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $115.00 to $142.00 in a research note on Friday, January 16th.

BioNTech Stock Performance

NASDAQ:BNTX opened at $113.75 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech has a fifty-two week low of $81.20 and a fifty-two week high of $124.98. The firm has a market cap of $25.61 billion, a PE ratio of -43.25 and a beta of 1.40. The business has a 50 day moving average price of $101.09 and a 200-day moving average price of $103.89.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.81 earnings per share. Equities research analysts predict that BioNTech will post -3.88 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently modified their holdings of BNTX. R Squared Ltd bought a new position in BioNTech in the fourth quarter worth about $323,000. Pictet Asset Management Holding SA grew its holdings in shares of BioNTech by 41.6% during the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company’s stock worth $8,457,000 after acquiring an additional 26,119 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of BioNTech by 2.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,075 shares of the company’s stock worth $1,721,000 after acquiring an additional 441 shares in the last quarter. B. Metzler seel. Sohn & Co. AG lifted its stake in shares of BioNTech by 19.1% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 4,457 shares of the company’s stock valued at $424,000 after purchasing an additional 715 shares during the period. Finally, Probity Advisors Inc. boosted its position in shares of BioNTech by 14.2% during the fourth quarter. Probity Advisors Inc. now owns 2,863 shares of the company’s stock valued at $273,000 after purchasing an additional 357 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.